# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Bionano Genomics, Inc. (NASDAQ:BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary b...
Scotiabank analyst Sung Ji Nam maintains Bionano Genomics (NASDAQ:BNGO) with a Sector Outperform and lowers the price target...
2024 OutlookWe remain hyper focused on our mission of transforming the way the world sees the genome. To that end we want to hi...
Bionano Genomics (NASDAQ:BNGO) reported quarterly sales of $10.721 million which beat the analyst consensus estimate of $10.585...
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...
Pre-print publication from Levy, et al. describes the second phase of a multisite evaluation and validation of optical genome m...
Bionano has completed the early access program for the Stratys™ system and is now making it available in a full commercial rele...